About SGN-CD33A

SGN-CD33A is an antibody-drug conjugate (ADC) targeting CD33, a protein that is expressed on most acute myeloid leukemia (AML) cells. SGN-CD33A employs our newest proprietary ADC technology. This technology comprises a potent cell-killing agent called a pyrrolobenzodiazepine (PBD) dimer that works by a different mechanism than auristatins. The PBD dimer is stably linked to an antibody with our site-specific engineered cysteines, resulting in uniform drug-loading of two PBD dimers per antibody. We call this engineered antibody an EC-mAb.


SGN-CD33A is in two phase 1 clinical trials designed to assess its safety and anti-leukemia activity in AML as a single agent and in combination with other standard treatments.

You are now leaving Seattle Genetics' site. Seattle Genetics does not necessarily endorse the organization associated with this link and takes no responsibility for the content contained therein. This resource link is for informational purposes only. Do you want to continue to the external site and leave

No, return to

Yes, leave